Background Patent foramen ovale (PFO) is a vestigial congenital cardiovascular structure
present in around 25% of adults. In most cases, PFO is entirely benign and requires no …

Background In patients with cryptogenic stroke, transcatheter (TC) closure of a patent
foramen ovale (PFO) has not been shown to better prevent recurrent vascular events than …

Patent foramen ovale (PFO) is frequently identified in young patients with ischemic stroke.
Randomized controlled trials provide robust evidence supporting PFO closure in selected …

Background: New evidence emerged recently regarding the percutaneous closure of patent
foramen ovale (PFO) to prevent recurrent stroke in patients with cryptogenic stroke. Purpose …

Objective: To update the 2004 American Academy of Neurology guideline for patients with
stroke and patent foramen ovale (PFO) by addressing whether (1) percutaneous closure of …

Importance Patent foramen ovale (PFO)–associated strokes comprise approximately 10% of
ischemic strokes in adults aged 18 to 60 years. While device closure decreases stroke …

Patent foramen ovale (PFO) is a normal fetal communication between the right and left atria
that persists after birth. PFO is a common finding that occurs in 20–34% of the population …

Until recently, evidence to support Patent Foramen Ovale (PFO) closure for secondary
prevention of recurrent stroke has been controversial. Publication of high‐quality evidence …

Foramen ovale is an embryonic defect in the interatrial septum which allows passage of
oxygenated blood from the right atrium to the left atrium. 1, 2 In about 75% of the population …

Objective To examine the relative impact of three management options in patients aged< 60
years with cryptogenic stroke and a patent foramen ovale (PFO): PFO closure plus …